{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastasis%2C+Neoplasm", "query": { "condition": "Metastasis, Neoplasm" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10633, "total_pages": 1064, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastasis%2C+Neoplasm&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-22T23:23:30.886Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05576896", "title": "Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IV Colorectal Cancer Positive for BRAF V600E Mutation", "Colorectal Cancer", "Colorectal Cancer Stage IV" ], "interventions": [ { "name": "Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2022-10-10", "completion_date": "2026-04-20", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-07-22T23:23:30.886Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05576896" }, { "nct_id": "NCT00513162", "title": "Valproate and Etoposide for Patients With Neuronal Tumors and Brain Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroectodermal Tumor", "Brain Metastases", "Advanced Cancer" ], "interventions": [ { "name": "Valproate", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 8, "start_date": "2007-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2012-09-19", "last_synced_at": "2026-07-22T23:23:30.886Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00513162" }, { "nct_id": "NCT04459273", "title": "Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Carcinoma", "Cervical Carcinoma", "Cholangiocarcinoma", "Hematopoietic and Lymphoid Cell Neoplasm", "Hepatocellular Carcinoma", "Malignant Adrenal Gland Neoplasm", "Malignant Brain Neoplasm", "Malignant Pleural Neoplasm", "Malignant Skin Neoplasm", "Malignant Solid Neoplasm", "Malignant Testicular Neoplasm", "Malignant Thymus Neoplasm", "Neuroendocrine Neoplasm", "Thyroid Gland Carcinoma", "Urothelial Carcinoma", "Cancer of Unknown Primary Site" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Gallium Ga 68 FAPi-46", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "18F-FDG", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2020-08-27", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-07-22T23:23:30.886Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04459273" }, { "nct_id": "NCT06937866", "title": "Maintenance Zanzalintinib With Etoposide After HDCT in GCT", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Germ Cell Tumor" ], "interventions": [ { "name": "Zanzalintinib", "type": "DRUG" }, { "name": "Etoposide Capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2025-11-12", "completion_date": "2031-09", "has_results": false, "last_update_posted_date": "2025-11-21", "last_synced_at": "2026-07-22T23:23:30.886Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT06937866" }, { "nct_id": "NCT02187302", "title": "CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Renal Cell Carcinoma" ], "interventions": [ { "name": "CRLX101", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Standard of Care (Investigator Choice)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NewLink Genetics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2014-07", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2020-05-28", "last_synced_at": "2026-07-22T23:23:30.886Z", "location_count": 38, "location_summary": "La Jolla, California • Los Angeles, California • Denver, Colorado + 33 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02187302" }, { "nct_id": "NCT04628780", "title": "Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small-cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Renal Cell Carcinoma", "Urothelial Carcinoma", "Colorectal Carcinoma", "Ovarian Carcinoma" ], "interventions": [ { "name": "PF-07209960", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2020-12-16", "completion_date": "2023-05-26", "has_results": true, "last_update_posted_date": "2024-07-29", "last_synced_at": "2026-07-22T23:23:30.886Z", "location_count": 13, "location_summary": "Duarte, California • Los Angeles, California • Santa Monica, California + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04628780" }, { "nct_id": "NCT03535727", "title": "A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adenocarcinoma", "Pancreatic Neoplasms", "Neoplasm, Glandular", "Neoplasms", "Neoplasms Pancreatic", "Digestive System Neoplasm", "Endocrine Gland Neoplasms", "Digestive System Disease", "Pancreatic Diseases", "Endocrine System Diseases" ], "interventions": [ { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "76 Years", "sex": "ALL", "summary": "18 Years to 76 Years" }, "enrollment_count": 48, "start_date": "2018-06-21", "completion_date": "2022-10-03", "has_results": true, "last_update_posted_date": "2024-12-31", "last_synced_at": "2026-07-22T23:23:30.886Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03535727" }, { "nct_id": "NCT04515394", "title": "Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Neoplasms" ], "interventions": [ { "name": "Tepotinib", "type": "DRUG" }, { "name": "Cetuximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2021-01-28", "completion_date": "2022-03-31", "has_results": true, "last_update_posted_date": "2022-12-22", "last_synced_at": "2026-07-22T23:23:30.886Z", "location_count": 13, "location_summary": "Phoenix, Arizona • La Jolla, California • Santa Monica, California + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04515394" }, { "nct_id": "NCT04575922", "title": "Nivolumab+Ipilimumab+RT in MSS mCRC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Microsatellite Stable Colorectal Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2020-10-05", "completion_date": "2024-06", "has_results": false, "last_update_posted_date": "2022-09-08", "last_synced_at": "2026-07-22T23:23:30.886Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04575922" }, { "nct_id": "NCT00528645", "title": "AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extensive Stage Small Cell Lung Cancer", "Lung Metastases", "Malignant Pleural Effusion", "Recurrent Small Cell Lung Cancer" ], "interventions": [ { "name": "saracatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2007-11", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2017-12-07", "last_synced_at": "2026-07-22T23:23:30.886Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00528645" } ] }